The combined message of these meta-analyses is that hyperactive mTOR associates with worse prognosis in gynecological and gastrointestinal cancers; it is not associated with worse prognosis in breast cancer or even associated with good prognosis in some breast cancer types [38] or in lung cancer [36]; and it is inconclusive (due to small sample sizes) in HNSCCs and prostate cancers. Here, MTOR is linked to lung cancer.